Thursday November 26 2009 | Biotechnology feed | All feeds
|
|
Selexys Pharmaceuticals Corporation
Download detailed PDF Members: Selexys Pharmaceuticals Corporation (Selexys) is a privately held company that develops and commercializes therapeutics to treat inflammatory and thrombotic diseases. The company has completed research and is in preclinical development of two drug candidates, a monoclonal antibody and a glycosulfopeptide, that have broad application for the treatment of acute and chronic inflammatory disorders. These compounds bind to and block the function of a protein called P-selectin, a key participant in the first stage of inflammation. Preventing P-selectin from recruiting destructive white blood cells to sites of inflammatory disease can potentially impact the disease mechanism for medical indications such as Sickle Cell Disease, Deep Vein Thrombosis, Asthma, Rheumatoid Arthritis, and Ischemia Reperfusion Injury in Stroke, Myocardial Infarction, and Organ Transplantation. In addition, Selexys has rights to soluble P-selectin which activates pro-coagulant processes by stimulating and recruiting tissue-factor rich microparticles to platelet aggregates. The company is seeking corporate partners for product development and commercialization.
This page has been viewed 439 times since April 2007, the link to the organisation's website has been followed 94 times Recent Search Terms used to find this page: Selexys Pharmaceuticals | selexys pharmaceuticals | search selexys pharmaceutical | selexy | selexy | Selexys | . Search for more companies in Oklahoma City Search for more companies in Oklahoma This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified. BioPortfolio search results for Selexys Pharmaceuticals Corporation | ||||||||||||||||||||||||||||||
|